JMIR Publications

ABSTRACT

The recent Coronavirus Disease 2019 (COVID-19) causes an immense health crisis to global public health. The etiological agent of COVID-19, a recently arose disease is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Presently, more research in the field of effecting vaccine against this emerged viral disease is indeed a need of the hour. In the current study, we collected SARS-CoV-2 genome which is prominent in India against human host, furthermore using reverse vaccinology here we prove effective vaccine candidates that can be milestone in the battle against COVID19. This novel study divulged one promising antigenic peptide GVYFASTEK from surface glycoprotein (protein accession no. - QIA98583.1) of SARS-CoV-2, which was predicted to be interacted with MHC alleles and showed up to 90% conservancy and high value of antigenicity. Subsequently, the molecular docking and simulation studies were verified molecular interaction of this prime antigenic peptide with the residues of HLA-A*11-01 allele for MHC Class I. After vigorous analysis, this peptide was predicted to be a suitable epitope that is capable to induce a strong cell-mediated immune response against the SARS-CoV-2. Consequences from the current study could facilitate selecting SARS-CoV-2 epitopes for vaccine production pipelines in the immediate future. This novel research will certainly pave the way for a fast, reliable and virtuous platform to provide timely countermeasure of this dangerous pandemic disease, COVID-19.